Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9000621 | 0.91 | FDPS (0.44) | POLBMMP8FDPSCYP4F2CYP4A11 | |
| SCHEMBL3889930 | 0.90 | MMP8 (0.37) | MMP8CYP2D6CYP2C9CYP2C19CYP4F2 | |
| SCHEMBL9234022 | 0.90 | FDPS (0.46) | FDPS | |
| SCHEMBL3674521 | 0.88 | FDPS (0.49) | FDPS | |
| SCHEMBL9380998 | 0.86 | CYP4F2 (0.36) | MMP8CYP4F2CYP4A11 | |
| SCHEMBL6784316 | 0.80 | SMN1; SMN2 (0.43) | POLBMMP8 | |
| SCHEMBL1932712 | 0.79 | MMP8 (0.36) | MMP8CYP2D6CYP2C9CYP2C19CYP4F2 | |
| SCHEMBL11595501 | 0.78 | CYP2D6 (0.36) | MMP8CYP2D6CYP2C9CYP2C19CYP4F2 | |
| SCHEMBL7267997 | 0.76 | MMP8 (0.34) | MMP8CYP4F2CYP4A11 | |
| SCHEMBL2356491 | 0.75 | FDPS (0.35) | POLBMMP8FDPSCYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2203161-B1 | QUINONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | UNIV INDIANA RES & TECH CORP (US) | 2018-05-09 | — | — | EP | disclosed |
| US-9089605-B2 | Quinone derivatives, pharmaceutical compositions, and uses thereof | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2015-07-28 | — | — | US | disclosed |
| US-20100297113-A1 | QUINONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | PURDUE RESEARCH FOUNDATION | 2010-11-25 | — | — | US | disclosed |
| EP-2203161-A1 | QUINONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Indiana University Research and Technology Corporation (US) | 2010-07-07 | — | — | EP | disclosed |
| WO-2009042544-A1 | QUINONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2009-04-02 | — | — | WO | disclosed |
| EP-0749428-B1 | ISOXAZOLINE COMPOUNDS AS INHIBITORS OF TNF RELEASE | PFIZER (US) | 1998-07-29 | — | — | EP | disclosed |
| EP-0730588-B1 | ISOXAZOLINE COMPOUNDS AS ANTIINFLAMMATORY AGENTS | PFIZER (US) | 1997-07-02 | — | — | EP | disclosed |
| EP-0655439-A2 | 5,6-Bicyclic glycoprotein IIb IIIa antagonists useful in inhibition of platelet aggregation | ELI LILLY AND COMPANY (US) | 1995-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100297113-A1 | QUINONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | APEX1, NQO1, REV1 | POLB 264/4885MMP8 4054/4885FDPS 1009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.